Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database ; volume:24 ; number:1 ; day:22 ; month:4 ; year:2023 ; pages:1-12 ; date:12.2023
BMC nephrology ; 24, Heft 1 (22.4.2023), 1-12, 12.2023
- Urheber
-
Chen, Pengwei
Zhu, Jianhong
Xu, Yanchun
Huang, Qiuyan
Su, Jianan
Gao, Ziqing
Feng, Min
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12882-023-03171-9
- URN
-
urn:nbn:de:101:1-2023090209253980921005
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chen, Pengwei
- Zhu, Jianhong
- Xu, Yanchun
- Huang, Qiuyan
- Su, Jianan
- Gao, Ziqing
- Feng, Min
- SpringerLink (Online service)
Ähnliche Objekte (12)
Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database
Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database
The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database
Relationship Between Clozapine and Non-Hematological Malignant Tumors: A Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System Database
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
Pharmacovigilance study of anti-infective-related acute kidney injury using the Japanese adverse drug event report database
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database
Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database
The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database
Relationship Between Clozapine and Non-Hematological Malignant Tumors: A Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System Database
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
Pharmacovigilance study of anti-infective-related acute kidney injury using the Japanese adverse drug event report database
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database
Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database
The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database
Relationship Between Clozapine and Non-Hematological Malignant Tumors: A Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System Database
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
Pharmacovigilance study of anti-infective-related acute kidney injury using the Japanese adverse drug event report database
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics